Treatment before surgery for stage 2–3 lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether giving a combination of three medicines before surgery can help shrink tumors in people with stage 2 or 3 non-small cell lung cancer, potentially making surgery and recovery more effective. The medicines include an immunotherapy drug (tislelizumab), a targeted therapy (anlotinib), and a chemotherapy drug (nab-paclitaxel).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stage 2 or 3 non-small cell lung cancer that the doctor thinks can be removed with surgery.
- You have not had any prior treatment for this cancer, such as chemotherapy, radiation, or other therapies.
- Your tumor does not have certain genetic mutations (or for a type called squamous cell carcinoma, the mutation status may not be known).
- You are generally in good health, able to perform daily activities, and have adequate organ function (kidneys, liver, blood counts).
- You are able to take oral medications and do not have conditions like bleeding disorders or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests a combination of three treatments given before surgery for lung cancer: targeted radiation (SBRT), an immunotherapy drug (tislelizumab), and a targeted therapy (anlotinib). The goal is to shrink the tumor and improve the chance of successful surgery.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and chemotherapy) given before and after surgery to treat stage II-IIIB non-small cell lung cancer. The goal is to see if this approach can improve outcomes for patients whose cancer can be removed surgically.
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
This trial tests a combination of radiation, an immunotherapy drug called tislelizumab, and chemotherapy given before surgery for non-small cell lung cancer that has not spread too far (stage II-III). The goal is to see if this approach can shrink tumors and improve outcomes.
Hear when a new Tislelizumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.